Gene Pharmaceuticals

GenePharma is a leading biotechnology company headquartered in Suzhou, China, specializing in the research and development of RNA interference (RNAi) and oligonucleotide-based therapeutics. The company leverages proprietary delivery technologies, including lipid nanoparticles (LNP) and GalNAc conjugation, to advance a pipeline of candidates targeting chronic Hepatitis B, oncology, and metabolic disorders. GenePharma's lead program, GP-101, is a siRNA-based therapy currently in clinical development for the treatment of Hepatitis B. Beyond its internal drug discovery efforts, the company is a major global provider of custom RNA synthesis services, research reagents, and CDMO solutions for the life sciences industry. GenePharma maintains state-of-the-art R&D and manufacturing facilities in Suzhou and Shanghai to support its integrated RNA technology platform.